M
Magnus Life Science
Magnus has those ideas and employs a novel approach to the advancement and rapid development of valuable new discoveries in biomedicine
About Magnus Life Science
Magnus Life Science, founded in 2013 by John Martin, operated as a London-based biomedical company focused on translating scientific research into therapeutic solutions. The firm was strategically based at University College London (UCL) to foster a close collaboration between commercially-driven scientists and academic researchers, with Professor John Martin, Chair of Cardiovascular Medicine at UCL, also serving as the company's Chief Scientist. The company's business model was centered on a "spin-in" approach, where it would acquire therapeutic assets and establish each as a distinct company, granting share ownership to the founding scientists.
Magnus Life Science successfully raised approximately $25 million (£15.5 million) in seed funding from a private equity investor, which was supplemented by €11.5 million in grants from the European Commission's Framework 7 (FP7) program for two of its key initiatives. The company's diverse research and development portfolio was unified by a central focus on understanding blood flow to treat a range of diseases. This portfolio was structured into several subsidiary programs, each targeting a high-unmet medical need. These included Magnus Oxygen, which was developing an injectable therapy to prevent reperfusion injury and chronic heart failure. Magnus Flow focused on a bio-magnetic and biodegradable stent for treating coronary artery stenosis. Other programs were Magnus Growth, aimed at therapies for placental insufficiencies; Magnus Life, developing small molecule immunotherapies for cancer; and Magnus Metabolic, which targeted the cardiovascular effects of Type II Diabetes and obesity. Despite its promising start and funding, the company is now reported as deadpooled.
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Oct 2014 | $20M | $82M | Undisclosed | — |
Growth signals
Latest recorded traffic for Magnus Life Science is 0 monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Magnus Life Science in the London ecosystem
The Magnus Life Science office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Magnus Life Science on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Magnus Life Science’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.










